ProMIS Neurosciences (PMN) Total Current Liabilities (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Total Current Liabilities came in at $6.6 million in Q1 2026, up 63.07% YoY from $4.1 million in Q1 2025, and down 36.47% on a QoQ basis from $10.4 million in Q4 2025.
ProMIS Neurosciences (PMN) Total Current Liabilities (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Total Current Liabilities data on file, last reported at $6.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 63.07% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 63.07% YoY) and the FY2025 annual result came in at $10.4 million, up 369.33% from the prior year.
- Total Current Liabilities declined to $6.6 million in Q1 2026, from $10.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $12.2 million in Q3 2025 to a low of $1.9 million in Q2 2022.
- A 5-year average of $6.4 million and a median of $6.5 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 590.26% — and 2024, when it tumbled 76.27%.
- Tracing PMN's Total Current Liabilities over 5 years: stood at $6.4 million in 2022, then jumped by 45.79% to $9.3 million in 2023, then plunged by 76.27% to $2.2 million in 2024, then surged by 369.33% to $10.4 million in 2025, then slumped by 36.47% to $6.6 million in 2026.
- The last three Total Current Liabilities figures came in at $6.6 million (Q1 2026), $10.4 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.22 Mn |
| Mar 31, 2026 | 6.61 Mn |
| Dec 31, 2025 | 10.41 Mn |
| Sep 30, 2025 | 12.21 Mn |
| Jun 30, 2025 | 9.82 Mn |
| Mar 31, 2025 | 4.06 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 3.17 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 9.35 Mn |
| Sep 30, 2023 | 9.85 Mn |
| Jun 30, 2023 | 8.74 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 6.41 Mn |
| Sep 30, 2022 | 3.10 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Dec 31, 2021 | 929,074.00 |